VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- May 24, 2007 -- Chemokine Therapeutics Corp. ("Chemokine" or the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced that it has amended certain terms of its license agreement with The University of British Columbia ("UBC") dated September 22, 1999. Under the terms of the license agreement with UBC, Chemokine was required to meet milestones and make milestone payments for certain technologies related to CTCE-9908 or CTCE-0214. The amendments to the license agreement with UBC modified these milestone obligations to align with the Company's current development plans.
